170 related articles for article (PubMed ID: 25600037)
21. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
Jordan J; Tank J; Heusser K; Heise T; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
J Am Soc Hypertens; 2017 Sep; 11(9):604-612. PubMed ID: 28757109
[TBL] [Abstract][Full Text] [Related]
22. Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.
Dailey G
J Diabetes; 2015 Jul; 7(4):448-61. PubMed ID: 25676662
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
24. Impact of empagliflozin in patients with diabetes and heart failure.
Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
26. Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus.
Lewin AJ; Frías JP
Expert Opin Pharmacother; 2015 Apr; 16(5):781-4. PubMed ID: 25644093
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
[TBL] [Abstract][Full Text] [Related]
28. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
29. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236
[TBL] [Abstract][Full Text] [Related]
30. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
31. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
Hu J; Zou P; Zhang S; Zhou M; Tan X
Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
[TBL] [Abstract][Full Text] [Related]
32. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
33. Extra-glycaemic properties of empagliflozin.
Solini A
Diabetes Metab Res Rev; 2016 Mar; 32(3):230-7. PubMed ID: 25994513
[TBL] [Abstract][Full Text] [Related]
34. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Muscelli E; Astiarraga B; Barsotti E; Mari A; Schliess F; Nosek L; Heise T; Broedl UC; Woerle HJ; Ferrannini E
Diabetologia; 2016 Apr; 59(4):700-8. PubMed ID: 26704626
[TBL] [Abstract][Full Text] [Related]
35. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
[TBL] [Abstract][Full Text] [Related]
37. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
38. SGLT2 inhibitors: new reports.
Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
[TBL] [Abstract][Full Text] [Related]
39. Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes.
Al-Jobori H; Daniele G; Cersosimo E; Triplitt C; Mehta R; Norton L; DeFronzo RA; Abdul-Ghani M
Diabetes; 2017 Jul; 66(7):1999-2006. PubMed ID: 28428225
[TBL] [Abstract][Full Text] [Related]
40. ▼ Empagliflozin, diabetes and outcomes.
Drug Ther Bull; 2016 Jul; 54(7):78-81. PubMed ID: 27417322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
